Prof Thierry Facon speaks to ecancer at ASH 2018 about results from the DARA trial.
He explains that the trial has found that daratumumab increases PFS in patients with transplant-ineligible multiple myeloma.
Prof Facon added that the trial is important as it has the potential to establish daratumumab as the new standard of care for patients with transplant-ineligible newly diagnosed multiple myeloma.
Read more about this work here.
Watch his press conference here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.